MX9706415A - Novedosos metodos para diagnosticar enfermedades prostaticas benignas. - Google Patents

Novedosos metodos para diagnosticar enfermedades prostaticas benignas.

Info

Publication number
MX9706415A
MX9706415A MX9706415A MX9706415A MX9706415A MX 9706415 A MX9706415 A MX 9706415A MX 9706415 A MX9706415 A MX 9706415A MX 9706415 A MX9706415 A MX 9706415A MX 9706415 A MX9706415 A MX 9706415A
Authority
MX
Mexico
Prior art keywords
patient
psa
benign prostatic
proportion
level
Prior art date
Application number
MX9706415A
Other languages
English (en)
Other versions
MXPA97006415A (es
Inventor
Albert A Luderer
Gran D Carlson
Robert P Thiel
Thomas F Soriano
William J Kramp
Original Assignee
Albert A Luderer
Gran D Carlson
Robert P Thiel
Thomas F Soriano
William J Kramp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert A Luderer, Gran D Carlson, Robert P Thiel, Thomas F Soriano, William J Kramp filed Critical Albert A Luderer
Publication of MX9706415A publication Critical patent/MX9706415A/es
Publication of MXPA97006415A publication Critical patent/MXPA97006415A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere a novedosos métodos para diagnosticar enfermedades prostáticas benignas (BPD), tal como la hiperplasia prostática benigna, prostatitis o atrofia glandular, en un paciente humano, hombre, sin requerir una biopsia. Se mide el nivel total del antígeno específico de la prostata (PSA) en la sangre o suero del paciente. Si el paciente tiene un nivel total del PSA entre aproximadamente 2.5 ng/ml y 10.0 ng/ml, entonces se mide el nivel libre del PSA en la sangre o suero de este paciente. Se calcula la proporcion del PSA libre al PSA total. Si esta proporcion es igual a, o mayor de, aproximadamente el 25%, entonces se diagnostica que el paciente tiene una BPD, opcionalmente, si el paciente tiene un nivel total de PSA entre 10.1 ng/ml y 20.0 ng/ml, entonces el nivel libre del PSA en la sangre o el suero del paciente puede también medirse. La proporcion del PSA libre al PSA total se calcula. Si esta proporcion es igual a o mayor del 25%, entonces se diagnostica que el paciente tiene una BPD.
MXPA/A/1997/006415A 1995-02-23 1997-08-22 Novedosos metodos para diagnosticar enfermedades prostaticas benignas MXPA97006415A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08393214 1995-02-23
US08/393,214 US5698402A (en) 1995-02-23 1995-02-23 Methods for diagnosing benign prostatic hyperplasia

Publications (2)

Publication Number Publication Date
MX9706415A true MX9706415A (es) 1998-07-31
MXPA97006415A MXPA97006415A (es) 1998-11-09

Family

ID=

Also Published As

Publication number Publication date
WO1996026441A1 (en) 1996-08-29
ATE223051T1 (de) 2002-09-15
EP0811162A1 (en) 1997-12-10
US6100049A (en) 2000-08-08
JP2001503129A (ja) 2001-03-06
EP0811162B1 (en) 2002-08-28
US5698402A (en) 1997-12-16
EP1221619A3 (en) 2002-08-07
CA2213709A1 (en) 1996-08-29
DE69623264D1 (de) 2002-10-02
DE69623264T2 (de) 2004-01-22
EP1221619A2 (en) 2002-07-10
EP0811162A4 (en) 1999-09-01
US5912135A (en) 1999-06-15
CA2213709C (en) 2009-01-27

Similar Documents

Publication Publication Date Title
EP0811162A4 (en) NEW DIAGNOSTIC METHODS FOR BENIGN PROSTATE CONDITIONS
Czarnocka et al. Purification of the human thyroid peroxidase and its identification as the microsomal antigen involved in autoimmune thyroid diseases
Jackson et al. An IgG autoantibody which inactivates C1-inhibitor
WO1995021601A3 (en) Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
ATE198513T1 (de) Ptpalpha-bestimmung in der tumordiagnose und - prognose
AU9779498A (en) Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
US4379839A (en) Method for detecting cancer
DK0433088T3 (da) Monoklonale antistoffer, der reagerer med et humant atheromaassocieret antigen
Baydanoff et al. Age-related changes in the level of circulating elastin-derived peptides in serum from normal and atherosclerotic subjects
NO920125L (no) Fremgangsmaate for aa bestemme den funksjonelle aktivitetentil fritt protein s eller protein c i en plasmaproeve
WO1995005604A3 (en) Methods for the diagnosis of alzheimer's disease
AU4623599A (en) Method for diagnosing an adenocarcinoma or a benign prostate pathology
AUPO943297A0 (en) Diagnostic test for alzheimer's disease
NO952385L (no) Fremgangsmåte til identifisering av individer med unormale celler som uttrykker HLA-A2/tyrosinasepeptidantigen
AU555699B2 (en) Pp13 protein from placenta
AU3851095A (en) Assay
AU2883597A (en) Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
Yoshikawa et al. The acquired vitamin K‐dependent γ‐carboxylation deficiency in hepatocellular carcinoma involves not only prothrombin, but also protein C
ATE323176T1 (de) Nachweis von brusttumorvirus-artigen sequenzen in brustkrebs bei menschen
AU2001267630A1 (en) Immunological test and diagnostic kit for prostate adenocarcinoma
CA2067797A1 (en) Production and use of human nm23 protein and antibodies therefor
CA2100464A1 (en) Prescreening of prostate cancer by serum prostatic specific antigen
Zolfaghari et al. Human lung membrane-bound neutral metallo-endopeptidase-catalyzed hydrolysis of bradykinin
Marchewka et al. N-acetyl-BD-glucosaminidase isoenzymes in the diagnosis of poisoning and kidney diseases
Seth et al. Serum gamma glutamyl transpeptidase in breast cancer